Side effects associated with current and prospective antimigraine pharmacotherapies

References

• Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitization. Lancet Neurol. 2009;8:679–690.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner J, Birbeck GL. Migraine: the seventh disabler. Cephalalgia. 2013;33:289–290.
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1–27.
   PubMed Web of Science ®Google Scholar
• Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124:309–323.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136:319–333.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12:570–584.
   PubMed Web of Science ®Google Scholar
• Villalón CM, MaassenVanDenBrink A. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev Med Chem. 2017;17:928–938.
   PubMed Web of Science ®Google Scholar
• Villalón CM, Centurión D, Valdivia LF, et al. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003;1:71–84.
   PubMedGoogle Scholar
• Olesen J, Goadsby PJ, Ramadan N, et al. The headaches. In: Olesen J, Goadsby PJ, Ramadan N, et al. editors. The Headaches. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1–1169.
   Google Scholar
• Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache. 2007;47(Suppl 1):S10–S19.
   PubMedGoogle Scholar
• Chan KY, Vermeersch S, de Hoon J, et al. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther. 2011;129:332–351.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–788.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017. DOI:10.1002/cpdd.345
   PubMed Web of Science ®Google Scholar
• Dib M. Optimizing prophylactic treatment of migraine: subtypes and patient matching. Ther Clin Risk Management. 2008;4:1061–1078.
   PubMedGoogle Scholar
• Dahlöf C, MaassenVanDenBrink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012;52:707–714.
   PubMed Web of Science ®Google Scholar
• Ramírez Rosas MB, Labruijere S, Villalón CM, et al. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013;14:1599–1610.
   PubMed Web of Science ®Google Scholar
• Gross RA, Johnston KC. Levels of evidence taking Neurology® to the next level. Neurology. 2009;72:8–10.
   PubMed Web of Science ®Google Scholar
• Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968–981.
   Google Scholar
• Fumal A, Schoenen J. Current migraine management – patient acceptability and future approaches. Neuropsych Dis Treat. 2008;4:1043–1057.
   PubMedGoogle Scholar
• Bolay H, Durham P. Pharmacology. In: Nappi G, Moskowitz M, editors. Headache. The Netherlands: Elsevier; 2011. p. 47–71.
   Google Scholar
• Brack A, Rittner HL, Schäfer M. Nichtopioidanalgetika zur perioperativen Schmerztherapie [Non-opioid analgesics for perioperative pain therapy. Risks and rational basis for use]. Anaesthesist. 2004;53: 263–280. German.
   PubMedGoogle Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–1345.
   Google Scholar
• Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1345.
   Web of Science ®Google Scholar
• Goadsby PJ, Liptom RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med. 2002;346:257–270.
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44:414–425.
   PubMed Web of Science ®Google Scholar
• Alexander SPH, Davenport AP, Kelly E, et al. The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol. 2015;172:5744–5869.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091–D1097.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–892.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–1107.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–1090.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–1100.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine. Efficacy at early time points. Neurology. 2016;87:41–48.
   PubMed Web of Science ®Google Scholar
• Benemei S, Nicoletti P, Capone JG, et al. CGRP receptors in the control of pain and inflammation. Curr Opin Pharmacol. 2009;9:9–14.
   PubMed Web of Science ®Google Scholar
• Hou M, Xing H, Cai Y, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18:42.
   PubMed Web of Science ®Google Scholar
• Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52(S5):13–23.
   PubMedGoogle Scholar
• Aydin D, Vuralli D, Akçali DT, et al. Metoclopramide inhibits trigeminovascular activation: evidence for effective acute attack treatment in migraine. Turk J Med Sci. 2017;47:343–347.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30:272–280.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144–166.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Guerrero-Toro C, Zakharov A, et al. Serotonergic mechanisms of trigeminal meningeal nociception: implications for migraine pain. Neuropharmacology. 2017;116:160–173.
   PubMed Web of Science ®Google Scholar
• Valdivia LF, Centuriόn D, Arulmani U, et al. 5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs. Naunyn-Schmiedeberg’s Arch Pharmacol. 2004;370:46–53.
   Google Scholar
• Marichal-Cancino BA, González-Hernández A, Manrique-Maldonado G, et al. Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935- and rauwolscine-sensitive receptors. Eur J Pharmacol. 2012;692:69–77.
   PubMed Web of Science ®Google Scholar
• Villalón CM, Galicia-Carreón J, González-Hernández A, et al. Pharmacological evidence that spinal α(2C)- and, to a lesser extent, α(2A)-adrenoceptors inhibit capsaicin-induced vasodilatation in the canine external carotid circulation. Eur J Pharmacol. 2012;683:204–210.
   PubMed Web of Science ®Google Scholar
• Pradalier A, Lantéri-Minet M, Géraud G, et al. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs. 2004;18:1149–1163.
   PubMed Web of Science ®Google Scholar
• Akin D, Gurdal H. Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery. Br J Pharmacol. 2002;136:177–182.
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Mitchell VA, Vaughan CW. Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn. Br J Pharmacol. 2012;165:1956–1965.
   PubMed Web of Science ®Google Scholar
• Wackenfors A, Jarvius M, Ingemansson R, et al. Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005;45:476–484.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25–30.
   PubMed Web of Science ®Google Scholar
• Moschiano F, Allais G, Grazzi L, et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci. 2005;26(Suppl 2):162–166.
   PubMedGoogle Scholar
• Hu Y, Guan X, Fan L, et al. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Head Pain. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Christensen AF, Esserlind AL, Werge T, et al. The influence of genetic constitution on migraine drug responses. Cephalalgia. 2016;36:624–639.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11:405–413.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - a randomised proof-of-concept trial. Cephalalgia. 2010;30:1170–1178.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011;31:748–750.
   PubMed Web of Science ®Google Scholar
• Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420–423.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion relation to the blood–brain barrier. Brain Res. 2015;1600:93–109.
   PubMed Web of Science ®Google Scholar
• Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608.
   PubMed Web of Science ®Google Scholar
• Wu H, Dall’Acqua WF. Humanized antibodies and their applications. Methods. 2005;36:1–2.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Hagen M, Gold M. Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine. Cephalalgia. 2014;34:1070–1078.
   PubMed Web of Science ®Google Scholar
• Tajti J, Majláth Z, Szok D, et al. Drug safety in acute migraine treatment. Exp Op Drug Saf. 2015;14:891–909.
   PubMed Web of Science ®Google Scholar
• Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.
   PubMedGoogle Scholar
• Boyer N, Signoret-Genest J, Artola A, et al. Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation. Pain. 2017;158:2025–2034.
   PubMed Web of Science ®Google Scholar
• Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2004;128:86–97.
   PubMed Web of Science ®Google Scholar
• Koella WP. CNS-related (side-) effects of β-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28:55–63.
   PubMed Web of Science ®Google Scholar
• Tekes K, Szegi P, Hashemi F, et al. Medicinal chemistry of antimigraine drugs. Curr Med Chem. 2013;20:3300–3316.
   PubMed Web of Science ®Google Scholar
• Wang DW, Mistry AM, Kahlig KM, et al. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol. 2010;1:144.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823.
   PubMed Web of Science ®Google Scholar
• Lakshmi CV, Singhi P, Malhi P, et al. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol. 2007;22:829–835.
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):3–9.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000;40:720–723.
   PubMed Web of Science ®Google Scholar
• Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81–84.
   PubMed Web of Science ®Google Scholar
• Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents: pharmacotherapy of gout. In: Brunton LL, editor. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. USA: McGraw-Hill; 2011. p. 954–1004.
   Google Scholar
• Tacconelli S, Bruno A, Grande R, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular safety-translating pharmacological data into clinical readouts. Exp Op Drug Saf. 2017;16:791–807.
   PubMed Web of Science ®Google Scholar
• Meek IL, van de Laar MAFJ, Vonkeman HE. Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks. Pharmaceuticals. 2010;3:2146–2162.
   Google Scholar
• Havanka H, Dahlöf C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Clin Ther. 2000;22:970–980.
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998;38:184–190.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraine A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997;49:1210–1218.
   PubMed Web of Science ®Google Scholar
• Meyler WJ. Side effects of ergotamine. Cephalalgia. 1996;16:5–10.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In: de Wolff FA, editor. Handbook of clinical neurology, Vol. 21 (65): intoxications of the nervous system, part II. Vol. 21. Amsterdam: Elsevier Science BV; 1995. p. 61–78.
   Google Scholar
• Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987;18:120–123.
   PubMed Web of Science ®Google Scholar
• Flexman AM, Del Vicario G, Schwarz S. Dark green blood in the operating theatre. Lancet. 2007;369:1972.
   PubMed Web of Science ®Google Scholar
• Fard JK, Hamzeiy H, Sattari M, et al. Triazole rizatriptan induces liver toxicity through lysosomal/mitochondrial dysfunction. Drug Res. 2016;66:470–478.
   PubMed Web of Science ®Google Scholar
• Lucaites VL, Krushinski JH, Schaus JM, et al. [3H] LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedeberg´S Arch Pharmacol. 2005;371:178–184.
   PubMed Web of Science ®Google Scholar
• Varnäs K, Hurd YL, Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse. 2005;56:21–28.
   PubMed Web of Science ®Google Scholar
• O’Quinn S, Davis RL, Guttermann DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia. 1999;19:223–231.
   PubMed Web of Science ®Google Scholar
• Welch KMA, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia. 2000;20:687–695.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltran E, Kristian H, Labastida A, et al. Lasmiditan and sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries. Cephalalgia. 2016;36(1S):104–105.
   Google Scholar
• Edvinsson L, Tfelt-Hansen P. The blood brain barrier in migraine treatment. Cephalalgia. 2008;28:1245–1258.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man. J Headache Pain. 2010;11:5–12.
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Goadsby PJ. Comparison of more and less lipophilic serotonin (5-HT1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol. 1998;150:45–51.
   PubMed Web of Science ®Google Scholar
• Jiménez-Mena LR, Gupta S, Muñoz-Islas E, et al. Clonidine inhibits the canine external carotid vasodilatation to capsaicin by a adrenoceptors. Eur J Pharmacol. 2006;543:68–76.
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood–brain barrier disruption. Br J Pharmacol. 1993;109:788–792.
   PubMed Web of Science ®Google Scholar
• Muñoz-Islas E, Lozano-Cuenca J, González-Hernández A, et al. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT_1B rather than 5-HT_1D receptors. Eur J Pharmacol. 2009;615:133–138.
   Google Scholar
• Weiller C, May A, Limroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658–660.
   PubMed Web of Science ®Google Scholar
• Schankin CJ, Maniyar FH, Seo Y, et al. Ictal lack of binding t brain parenchyma suggest integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016;139:1994–2001.
   PubMed Web of Science ®Google Scholar
• Ala-Hurula V, Myllyla VV, Arvela P, et al. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol. 1979;16:355–360.
   PubMed Web of Science ®Google Scholar
• Hougaard A, Amin FM, Christensen CE, et al. Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017;2017(140):1633–1642.
   Google Scholar
• Villalón CM, De Vries P, Rabelo G, et al. Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. Br J Pharmacol. 1999;126:585–594.
   PubMed Web of Science ®Google Scholar
• Cortijo J, Marti-Cabrera M, Bernabeu E, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol. 1997;122:1455–1463.
   PubMed Web of Science ®Google Scholar
• Labruijere S, Chan KY, de Vries R, et al. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. Cephalalgia. 2015;35:182–189.
   PubMed Web of Science ®Google Scholar
• Chan KY, De Vries R, Leijten FP, et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol. 2009;619:61–67.
   PubMed Web of Science ®Google Scholar
• De Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther. 2000;68:418–426.
   PubMed Web of Science ®Google Scholar
• Vanmolkot FH, De Hoon JN. Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform. Clin Pharmacol Ther. 2006;80:85–94.
   PubMed Web of Science ®Google Scholar
• Fishman GI, Chugh S, DiMarco JP, et al. Sudden cardiac death prediction and prevention report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society workshop. Circulation. 2010;122:2335–2348.
   Google Scholar
• Diener HC, Holle D, Solbach K, et al. Medication-overuse headache: risk, factors, pathophysiology and management. Nat Rev Neurol. 2016;12:575–583.
   PubMed Web of Science ®Google Scholar
• Chiang -C-C, Schwedt TJ, Wang S-J, et al. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36:371–386.
   PubMed Web of Science ®Google Scholar
• Westergaard ML, Hansen EH, Glumer C, et al. Definitions of medication overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34:409–425.
   PubMed Web of Science ®Google Scholar
• Westergaard ML, Glumer C, Hansen EH, et al. H. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain. 2014;155:2005–2013.
   PubMed Web of Science ®Google Scholar
• Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9:391–401.
   PubMed Web of Science ®Google Scholar
• Limmroth V, Kazarawa S, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59:1011–1014.
   PubMed Web of Science ®Google Scholar
• Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005;26:62–68.
   PubMed Web of Science ®Google Scholar
• De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67:325–337.
   PubMed Web of Science ®Google Scholar
• De Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010;133:2475–2488.
   PubMed Web of Science ®Google Scholar
• Supornsilpchai W, Le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010;30:1101–1109.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Chong CD. Medication overuse headache: pathophysiological insights from structural and functional brain MRI research. Headache. 2017;57:1173–1178.
   PubMed Web of Science ®Google Scholar
• Bongsebandhu-Phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep. 2012;16:110–115.
   PubMed Web of Science ®Google Scholar
• Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2001;2:695–703.
   PubMed Web of Science ®Google Scholar
• Gupta S, Mehrotra S, Villalόn CM, et al. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol. 2006;530:107–116.
   PubMed Web of Science ®Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the CGRP receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010;334:746–752.
   PubMed Web of Science ®Google Scholar
• Behm MO, Blanchard RL, Murphy MG, et al. Assessment of the effect of MK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease. Headache. 2008;48(Suppl 1):S39.
   Google Scholar
• Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:459–466.
   Web of Science ®Google Scholar
• Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004;24:645–656.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110.
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–1312.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123.
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970–977.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Emerging target‐based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013;93:78–85.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–722.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–584.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Eisenberg J, Yang J. Human blood–brain barrier insulin receptor. J Neurochem. 1985;44:1771–1778.
   PubMed Web of Science ®Google Scholar
• Wang Y, Welty DR. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm Res. 1996;13:398–403.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalagia. 2014;34:968–976.
   PubMed Web of Science ®Google Scholar
• Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine [Internet]. [cited Oct 2017]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly
   Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–390.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Kawasaki H, Imamura T, et al. Endogenous calcitonin gene-related peptide mediates nonadrenergic noncholinergic depressor response to spinal cord stimulation in the pithed rat. Circ Res. 1992;71:357–364.
   PubMed Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, et al. Heteroreceptors modulating CGRP release at neurovascular junction: potential therapeutic implications on some vascular-related diseases. BioMed Res Int. 2016;2016:2056786.
   PubMed Web of Science ®Google Scholar
• Arulmani U, Schuijt MP, Heiligers JPC, et al. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on α-CGRP induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol. 2004;94:291–297.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2014;34:483–492.
   PubMed Web of Science ®Google Scholar
• Walter S, Alibhoy A, Escandon R. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6:871–878.
   PubMed Web of Science ®Google Scholar
• Avilés-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, et al. Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol. 2017;174:2001–2014.
   PubMed Web of Science ®Google Scholar
• Gulbenkian S, Opgaard OS, Ekman R, et al. Peptidergic innervation of human epicardial coronary arteries. Circ Res. 1993;73:579–588.
   PubMed Web of Science ®Google Scholar
• Pascual J. CGRP antibodies: the Holy Grail for migraine prevention? Lancet Neurol. 2015;14:1066–1067.
   PubMed Web of Science ®Google Scholar
• Mai TH, Wu J, Diedrich A, et al. Calcitonin gene- peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J Am Soc Hyper. 2014;8:286–296.
   PubMed Web of Science ®Google Scholar
• Oh-Hashi Y, Shindo T, Kurihara Y, et al. Elevated sympathetic nervous activity in mice deficient in α-CGRP. Circulation. 2001;89:983–990.
   Web of Science ®Google Scholar
• Smillie SJ, King R, Kodji X, et al. An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014;63:1056–1062.
   PubMed Web of Science ®Google Scholar
• Struthers AD, Brown MJ, MacDonald DW, et al. Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin Sci. 1986;70:389–393.
   PubMed Web of Science ®Google Scholar
• Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25:139–147.
   PubMed Web of Science ®Google Scholar
• Berger A, Bloudek LM, Varon SF, et al. Adherence with migraine prophylaxis in clinical practice. Pain Practice. 2012;12:541–549.
   PubMed Web of Science ®Google Scholar
• Deen M, Edvige C, Katharina K, et al. Blocking CGRP in migraine patients–a review of pros and cons. J Head Pain. 2017;18:96.
   PubMed Web of Science ®Google Scholar
• Sarrouilhe D, Dejean C, Mesnil M. Involvement of gap junction channels in the pathophysiology of migraine with aura. Front Physiol. 2014;5:78.
   PubMed Web of Science ®Google Scholar
• Chan WN, Evans JM, Hadley MS, et al. Identification of (−)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3, 4-dihydro-2, 2-dimethyl-2H-benzo [b] pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett. 1999;9:285–290.
   PubMed Web of Science ®Google Scholar
• Smith MI, Read SJ, Chan WN, et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia. 2000;20:546–553.
   PubMed Web of Science ®Google Scholar
• Parsons AA, Bingham S, Raval P, et al. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001;132:1549–1557.
   PubMed Web of Science ®Google Scholar
• Dahlof CGH, Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia. 2009;29(Suppl 2):7–16.
   PubMed Web of Science ®Google Scholar
• Wang S-J, Chen P-K, Fuh J-L. Comorbidities of migraine. Front Neurol. 2010;1:16.
   PubMedGoogle Scholar
• Napoletano F, Lionetto L, Martelletti P. Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opin Pharmacother. 2014;15:303–305.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12:399–406.
   PubMed Web of Science ®Google Scholar
• Benemei S, Cortese F, Labastida-Ramírez A, et al. School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. 2017;18:103.
   PubMedGoogle Scholar
• Capi M, Curto M, Lionetto L, et al. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016;9:414–423.
   PubMed Web of Science ®Google Scholar
• Capi M, De Andrés F, Lionetto L,G, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26:227–234.
   PubMed Web of Science ®Google Scholar